Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Blood Advances
Alexander RöthJong Wook Lee

Abstract

Ravulizumab (ALXN1210), a humanized monoclonal antibody to complement component C5, was engineered from eculizumab to have a substantially longer terminal half-life, permitting longer dosing intervals for paroxysmal nocturnal hemoglobinuria (PNH) treatment. Two phase 1b/2 multicenter open-label studies evaluated efficacy and safety of multiple doses and regimens of ravulizumab in PNH patients naive to complement-inhibitor treatment. Patients in study 103 (n = 13) received ravulizumab 900 mg (lower trough exposure) or 1800 mg every 4 weeks (higher trough exposure); those in study 201 (n = 26) received 1000 mg every 4, 1600 mg every 6, 2400 mg every 8, or 5400 mg every 12 weeks. Trough exposure levels with study 201 dosing regimens were similar to the study 103 900-mg every-4-weeks regimen. Rapid sustained reduction of plasma lactate dehydrogenase (LDH) occurred across all cohorts (73%-90% at end point vs baseline). A greater proportion of patients had normalized LDH (<234 U/L) at least once from days 29 to 253 in the higher- (85.7%) vs lower-trough-exposure (50.0%-83.3%) cohorts; the weighted average of the proportion of instances of LDH normalization from days 29 to 253 was highest in higher- vs lower-trough-exposure cohorts (6...Continue Reading

References

Jul 1, 1991·Clinical Microbiology Reviews·J E Figueroa, P Densen
Nov 9, 1995·The New England Journal of Medicine·P HillmenJ V Dacie
Sep 27, 2003·Clinical Therapeutics·Anke RichterSusan L Dennett
Sep 23, 2006·The New England Journal of Medicine·Peter HillmenLucio Luzzatto
Apr 24, 2013·Blood·Anita HillPeter Hillmen
Dec 23, 2015·American Journal of Hematology·Michael LoschiRegis Peffault de Latour
Apr 25, 2017·Blood Cells, Molecules & Diseases·Mustafa N YenerelJeff Szer

❮ Previous
Next ❯

Citations

Feb 6, 2020·Expert Opinion on Biological Therapy·Jong Wook Lee, Austin G Kulasekararaj
Mar 25, 2019·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·William M BaldwinRobert L Fairchild
Sep 20, 2019·Therapeutic Advances in Hematology·Robert M Stern, Nathan T Connell
Jun 17, 2020·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Stanley C JordanAshley Vo
Jul 22, 2019·Nature Reviews. Drug Discovery·Dimitrios C MastellosJohn D Lambris
Feb 9, 2019·Blood·Nathan T Connell
Feb 16, 2019·Drugs·Kate McKeage
Nov 19, 2019·Experimental & Molecular Medicine·Tae Hyun Kang, Sang Taek Jung
Oct 6, 2020·Frontiers in Immunology·Ingrid AnemanLana McClements
Oct 13, 2020·Frontiers in Pharmacology·Chandan SarkarDaniela Calina
Dec 1, 2020·Expert Opinion on Drug Safety·Sung-Eun Lee, Jong Wook Lee
Jan 17, 2021·Cells·María Galindo-Izquierdo, José Luis Pablos Alvarez
May 9, 2021·Critical Reviews in Clinical Laboratory Sciences·Maria Alice V WillrichAshley Frazer-Abel
Jul 23, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Salma N TammamSanjay Mathur
Aug 7, 2021·British Journal of Haematology·Antonio Maria Risitano, Régis Peffault de Latour
Aug 19, 2021·ACS Chemical Biology·Alex MacphersonAlastair D G Lawson
Dec 4, 2019·Current Drug Discovery Technologies·Alaa Bedair, Fotouh R Mansour
Jan 9, 2022·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Christopher NelkeJan D Lünemann
Jan 27, 2022·Expert Opinion on Emerging Drugs·Camilla FrieriFlore Sicre De Fontbrune

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.